Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Adverse effects of SGLT2 inhibitors on bone health.

Literature DB >> 29875481

Adverse effects of SGLT2 inhibitors on bone health.

Jenny E Blau¹, Simeon I Taylor².

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2018 PMID： 29875481 PMCID： PMC6138556 DOI： 10.1038/s41581-018-0028-0

Source DB: PubMed Journal: Nat Rev Nephrol ISSN： 1759-5061 Impact factor: 28.314

× No keyword cloud information.

5 in total

1. Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study.

Authors: Jenny E Blau; Viviana Bauman; Ellen M Conway; Paolo Piaggi; Mary F Walter; Elizabeth C Wright; Shanna Bernstein; Amber B Courville; Michael T Collins; Kristina I Rother; Simeon I Taylor
Journal: JCI Insight Date: 2018-04-19

Review 2. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.

Authors: Ralph A DeFronzo; Luke Norton; Muhammad Abdul-Ghani
Journal: Nat Rev Nephrol Date: 2016-12-12 Impact factor: 28.314

3. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.

Authors: Nelson B Watts; John P Bilezikian; Keith Usiskin; Robert Edwards; Mehul Desai; Gordon Law; Gary Meininger
Journal: J Clin Endocrinol Metab Date: 2015-11-18 Impact factor: 5.958

4. Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.

Authors: John P Bilezikian; Nelson B Watts; Keith Usiskin; David Polidori; Albert Fung; Daniel Sullivan; Norm Rosenthal
Journal: J Clin Endocrinol Metab Date: 2015-11-18 Impact factor: 5.958

5. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.

Authors: Donald E Kohan; Paola Fioretto; Weihua Tang; James F List
Journal: Kidney Int Date: 2013-09-25 Impact factor: 10.612

5 in total

10 in total

1. Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis.

Authors: Maarten A de Jong; Sergei I Petrykiv; Gozewijn D Laverman; Antonius E van Herwaarden; Dick de Zeeuw; Stephan J L Bakker; Hiddo J L Heerspink; Martin H de Borst
Journal: Clin J Am Soc Nephrol Date: 2018-12-17 Impact factor: 8.237

Review 2. Effect of type 2 diabetes medications on fracture risk.

Authors: Cristian Guja; Loreta Guja; Rucsandra Dănciulescu Miulescu
Journal: Ann Transl Med Date: 2019-10

3. Fracture Risk of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease.

Authors: Andrea Cowan; Nivethika Jeyakumar; Yuguang Kang; Stephanie N Dixon; Amit X Garg; Kyla Naylor; Matthew A Weir; Kristin K Clemens
Journal: Clin J Am Soc Nephrol Date: 2022-05-26 Impact factor: 10.614

4. Type 2 diabetes in youth: Rationale for use of off-label antidiabetic agents.

Authors: Megan M Kelsey; Philip S Zeitler; Kristen J Nadeau; Amy S Shah
Journal: Pediatr Diabetes Date: 2022-05-16 Impact factor: 3.409

Review 5. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.

Authors: André J Scheen
Journal: Nat Rev Endocrinol Date: 2020-08-27 Impact factor: 43.330

Review 6. Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection fraction.

Authors: Mouhamed Nashawi; Omar Sheikh; Ayman Battisha; Mahnoor Mir; Robert Chilton
Journal: Heart Fail Rev Date: 2022-01 Impact factor: 4.214